Baker Botts represented Novacap and its Portfolio Company Cadent, while McDermott Will & Emery represented AdTheorent Holding Company in the transaction. Cadent, one of the largest...
Cadent’s $324 Million Acquisition of AdTheorent Holding Company
DISH and Sling TV LLC’s Victory in ITC Patent Dispute
Baker Botts advised DISH DBS Corp. DISH Technologies, L.L.C., and Sling TV L.L.C on the deal. DISH DBS Corp. DISH Technologies, L.L.C., and Sling TV L.L.C...
Alvarium Investments’ $1.4 Billion Business Combination with Tiedemann Group and Cartesian Growth Corporation
Goodwin Procter and Appleby advised Alvarium Investments on the deal. Seward & Kissel represented Tiedemann Advisors and TIG Advisors. Homburger advised Tiedemann Group and its Switzerland-based...
Cirkul’s $70 Million Series C Financing
Gunderson Dettmer advised Cirkul on the deal. Consumer-tech beverage client Cirkul, a producer of flavored cartridges and proprietary water bottles, announced its $70 million Series C...
Senti Biosciences’ Business Combination with Dynamics Special Purpose Corp.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
Cint Group AB’s $1.07 Billion Acquisition of Lucid
Kirkland & Ellis and Gernandt & Danielsson advised Cint Group AB on the deal, while Goodwin Procter represented Lucid Holdings, LLC. Cint Group AB (publ), a...
G Squared Ascend I’s Business Combination Agreement with Transfix
Goodwin Procter advised G Squared Ascend I on the deal. Latham & Watkins represented Transfix. G Squared Ascend I (NYSE: GSQD), a special purpose acquisition company...
Amryt Pharma’s Acquisition of Chiasma
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
Rubius Therapeutics’ $200 Million Underwritten Public Offering
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...